Extrapleural pneumonectomy in malignant pleural mesothelioma

BMJ (Online)

Volumn 343, Issue 7835, 2011, Pages

  Rena, Ottavio ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PATIENT; CANCER SURVIVAL; COMORBIDITY; DECORTICATION; EDITORIAL; EXTRAPLEURAL PNEUMONECTOMY; HUMAN; LUNG RESECTION; MALIGNANT MESOTHELIOMA; MEDICAL RESEARCH; PALLIATIVE THERAPY; PLEURA MESOTHELIOMA; PLEURECTOMY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; SURGICAL MORTALITY; SURGICAL TECHNIQUE; SURVIVAL TIME; SYMPTOM; TREATMENT INDICATION; VIDEO ASSISTED THORACOSCOPIC SURGERY; MESOTHELIOMA; METHODOLOGY; PLEURA TUMOR; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS; PNEUMONECTOMY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 83255170931     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d5706     Document Type: Editorial

References (12)

1. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999;79:666-72. (Pubitemid 29046253)
2. Graaf-Strukowska L, van der Zee J, van Putten W, Sesan S. Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura. Int Radiat Oncol Biol Phys 1999;43:511-6.
3. Vogelzang NJ, Rusthoven JJ, Symanowski J. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2002;21:2636-44.
4. Butchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax 1976;31:15-24.
5. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WS, Strauss GM, Corson JM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardovasc Surg 1999;117:54-65. (Pubitemid 29022249)
6. Maggi G, Casadio C, Cianci R, Rena O, Ruffini E. Trimodality management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 2001;19:346-50. (Pubitemid 32197443)
7. Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, Harrison L, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural meothelioma. J Thorac Cardiovasc Surg 2001;122:788-95.
8. Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011;12:763-72.
9. Nakas A, Trousse DS, Martin-Ucar AE, Waller DA. Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy. Eur J Cardiothorac Surg 2008;34:886-91.
10. Teh E, Fiorentino F, Tan C, Treasure T. A systematic review of lung-sparing extirpative surgery for pleural mesothelioma. J R Soc Med 2010;104:69-80.
11. Rena O, Boldorini LR, Gaudino E, Casadio C. Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations. J Surg Oncol 2011; online 21 March; doi:10.1002/jso.21901.
12. Fennell DA. Genetics and molecular biology of mesothelioma. Recent Results Cancer Res 2011;189:149-67.